Rxivist logo

ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth

By Jarrett R Remsberg, Radu M. Suciu, Noemi A Zambetti, Thomas W Hanigan, Ari J. Firestone, Anagha Inguva, Amy Long, Nhi Ngo, Kenneth M. Lum, Cassandra L Henry, Stewart K Richardson, Marina Predovic, Ben Huang, Amy R Howell, Micah J. Niphakis, Kevin Shannon, Benjamin F Cravatt

Posted 21 May 2020
bioRxiv DOI: 10.1101/2020.05.21.108316

A subset of Ras proteins, including N-Ras, depend on a palmitoylation/depalmitoylation cycle to regulate their subcellular trafficking and oncogenicity. General lipase inhibitors such as Palmostatin M block N-Ras depalmitoylation, but lack specificity and target several enzymes displaying depalmitoylase activity. Here, we describe ABD957, a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, and show that this compound impairs N-Ras depalmitoylation in human acute myeloid leukemia (AML) cells. ABD957 produced partial effects on N-Ras palmitoylation compared to Palmostatin M, but was much more selective across the proteome, reflecting a plasma membrane-delineated action on dynamically palmitoylated proteins. Finally, ABD957 impaired N-Ras signaling and the growth of NRAS-mutant AML cells in a manner that synergizes with MEK inhibition. Our findings uncover a surprisingly restricted role for ABHD17 enzymes in modulating the N-Ras palmitoylation cycle and suggest that ABHD17 inhibitors may have value as targeted therapies for NRAS-mutant cancers. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,075 times
  • Download rankings, all-time:
    • Site-wide: 19,494
    • In cancer biology: 464
  • Year to date:
    • Site-wide: 15,393
  • Since beginning of last month:
    • Site-wide: 20,443

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide